美国食品和药物管理局正在考虑更新HRT警告, 引用年轻女性的风险较低和新的证据. FDA weighs updating HRT warning, citing lower risks for younger women and new evidence.

林业发展局正在考虑更新2003年关于更年期激素替代疗法(HRT)的黑盒警告,并列举了新的证据,表明癌症和血栓等风险可能不适用于在更年期附近开始治疗的年轻妇女。 The FDA is considering updating the 2003 black box warning on hormone replacement therapy (HRT) for menopause, citing new evidence that risks like cancer and blood clots may not apply to younger women starting treatment near menopause. 以妇女健康倡议研究为基础的当前警告促使处方下降70%。 The current warning, based on the Women’s Health Initiative study, has contributed to a 70% drop in prescriptions. 美国食品和药物管理局的咨询小组建议修订或删除警告,特别是在局部雌激素治疗中,如乳液和环,这可能会造成较低的系统风险. An FDA advisory panel recommended revising or removing the warning, especially for localized estrogen treatments like creams and rings, which may pose lower systemic risks. 专家们说,已经过时的警告造成了不必要的恐惧,并限制了获得有效症状救济的机会。 Experts say the outdated warning has caused unnecessary fear and limited access to effective symptom relief. 预计FDA将很快宣布其决定, 敦促妇女咨询医疗服务提供者, 权衡个体风险和益处. The FDA is expected to announce its decision soon, urging women to consult healthcare providers to weigh individual risks and benefits.